Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ: TELO )

4.240 -0.230 (-5.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Telomir Pharmaceuticals, Inc. - Common Stock

Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study 
Via News Direct
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Unveils Preclinical Success of Telomir-1 in Age-Reversal Science
Via Investor Brand Network
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Via ACCESSWIRE
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO), Science of Longevity Featured in Upcoming Episode of “Health Uncensored with Dr. Drew”
Via Investor Brand Network
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Via ACCESSWIRE
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Via ACCESSWIRE
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs 
Via News Direct
BioMedNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor
Via Investor Brand Network
Exposures Product Safety
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
Via ACCESSWIRE
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024
Telomir Pharmaceuticals just reported results for the second quarter of 2024. 
Via InvestorPlace
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging 
Via News Direct
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024
Telomir Pharmaceuticals just reported results for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
Via Benzinga
Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Shares of AppLovin Corporation (NASDAQ: APP) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial 
Via Benzinga
Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures trading higher by around 70 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.